Literature DB >> 15506891

Ethanol palatability and consumption by high ethanol-drinking rats: manipulation of the opioid system with naltrexone.

Daniel L Coonfield1, Stephen W Kiefer, Frank M Ferraro, John David Sinclair.   

Abstract

Three experiments examined the effect of acute naltrexone treatment on both taste reactivity and consumption of ethanol in high ethanol-preferring rat lines: Alko Alcohol-Accepting (AA) rats (Experiments 1 and 2) and Alcohol-Preferring (P) rats (Experiment 3). A 3.0 mg/kg naltrexone dose was ineffective at altering ethanol palatability for either line, whereas 7.5 mg/kg was effective at reducing palatability of 10% ethanol for AA, but not P, rats, as reflected by both a decrease in ingestive responding and an increase in aversive responding. The effects of naltrexone on ethanol consumption were quite consistent: At both dosages, acute naltrexone treatment significantly decreased consumption of 10% ethanol. Termination of naltrexone resulted in an immediate increase in ethanol consumption to control levels. Results show that ethanol palatability and consumption can be dissociated in the rat and that the organization of opioidergic mechanisms that mediate ethanol responses may vary between rat lines. Copyright 2004 APA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15506891     DOI: 10.1037/0735-7044.118.5.1089

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  9 in total

1.  Region-specific induction of FosB/ΔFosB by voluntary alcohol intake: effects of naltrexone.

Authors:  Jing Li; Yunhui Cheng; Weiliang Bian; Xiaojun Liu; Chunxiang Zhang; Jiang-Hong Ye
Journal:  Alcohol Clin Exp Res       Date:  2010-07-09       Impact factor: 3.455

Review 2.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

3.  Mu-opioid receptor activation in the medial shell of nucleus accumbens promotes alcohol consumption, self-administration and cue-induced reinstatement.

Authors:  Jocelyn M Richard; Howard L Fields
Journal:  Neuropharmacology       Date:  2016-04-14       Impact factor: 5.250

Review 4.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

Review 5.  Alcohol response and consumption in adolescent rhesus macaques: life history and genetic influences.

Authors:  Melanie L Schwandt; Stephen G Lindell; Scott Chen; J Dee Higley; Stephen J Suomi; Markus Heilig; Christina S Barr
Journal:  Alcohol       Date:  2010-02       Impact factor: 2.405

Review 6.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

7.  Pharmacological effects of ethanol on ingestive behavior of the preweanling rat.

Authors:  Andrey P Kozlov; Michael E Nizhnikov; Elena I Varlinskaya; Norman E Spear
Journal:  Behav Brain Res       Date:  2009-06-21       Impact factor: 3.332

8.  Acute effects of naltrexone and GBR 12909 on ethanol drinking-in-the-dark in C57BL/6J mice.

Authors:  N K Kamdar; S A Miller; Y M Syed; R Bhayana; T Gupta; J S Rhodes
Journal:  Psychopharmacology (Berl)       Date:  2007-02-02       Impact factor: 4.415

9.  Baclofen and naltrexone, but not N-acetylcysteine, affect voluntary alcohol drinking in rats regardless of individual levels of alcohol intake.

Authors:  A Maryse Minnaard; Geert M J Ramakers; Louk J M J Vanderschuren; Heidi M B Lesscher
Journal:  Behav Pharmacol       Date:  2021-04-01       Impact factor: 2.277

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.